| Abstract|| |
The major long-term complications of renal transplantation (RT) include cardiovascular disease, opportunistic infections, malignancies, and chronic allograft nephropathy. Longterm complications are generally considered as those occurring more than 1 year post transplantation; however, some of the complications can occur earlier. We present a 58-year-old man who presented with multiple complications of RT concurrently and relatively early post transplantation including Kaposi's sarcoma, tuberculosis and allograft dysfunction.
Keywords: Renal transplantation, Complications, Tuberculosis, Kaposi′s sarcoma, Chronic allograft dysfunction
|How to cite this article:|
Alshaebi F, Adamu B, Alghareeb W. Concurrent Kaposi's sarcoma, tuberculosis, and allograft dysfunction in a renal transplant patient. Saudi J Kidney Dis Transpl 2009;20:270-3
|How to cite this URL:|
Alshaebi F, Adamu B, Alghareeb W. Concurrent Kaposi's sarcoma, tuberculosis, and allograft dysfunction in a renal transplant patient. Saudi J Kidney Dis Transpl [serial online] 2009 [cited 2022 Nov 28];20:270-3. Available from: https://www.sjkdt.org/text.asp?2009/20/2/270/45577
| Introduction|| |
Renal transplantation (RT) is currently the standard of care for the treatment of end- stage renal disease. However, the post-transplantation period is hampered by many potential complications which can lead to morbidity and/or mortality.
The three most commonly defined causes of death in the late post transplant period are cardiovascular disease (CVD), infection, and malignancy.  Chronic allograft dysfunction on the other hand accounts for 50% of allograft loss after the first year post transplant. These complications usually occur in the late posttransplantation period, but can present relatively early.
There have been reports of co-existence of opportunistic infections and malignancies, ,,,, as well as more than one opportunistic infection in the same patient.  We report the occurence of opportunistic infection, malignancy, chronic allograft dysfunction, and cardiovascular disease all co-existing in the same patient, relatively early in the post-transplantation period.
| Case Report|| |
A 58-year-old Saudi man with a history of end-stage renal disease secondary to diabetic nephropathy received live unrelated kidney transplantation abroad 8 months prior to presentation to our center, and he was followed up at peripheral local hospital. His immunosuppressant regime consisted of cyclosporine 100 mg BID, mycophenolate mofetil 500 mg BID and prednisolone 5 mg QD.
The patient presented with a 3-month history of intermittent fever and generalized non-pruritic, painless pigmented skin lesions, first noticed on the limbs then other parts of the body. He also complained of headaches and neck pain with restricted neck movements for 1 month earlier. He had been unable to walk without support for about 3 weeks prior to presentation. However, there was no history of a significant weight loss. His past history was remarkable for a single vessel ischemic heart disease stented 4 years prior to transplantation. The review of the systems was otherwise unremarkable.
On examination, the patient was febrile (38.2°C) and looked sick. His blood pressure (BP) was 175/76 mmHg. Skin examination was remarkable for nodular, violaceous skin lesions [Figure 1] that involved both upper and lower limbs, trunk, scalp, ear lobes, face, and hard palate, dull percussion notes on the left lung base with decreased intensity of breath sounds, neck stiffness with a negative Kernig's sign, and mild ankle edema. However, there was no significant peripheral lymphadenopathy, abnormal heart sounds or abnormal nervous system examination.
Laboratory investigations included cerebrospinal fluid biochemistry that was normal and stain negative for fungi and acid fast bacilli. Tuberculin skin test was negative. Urinalysis showed protein 1+ and microscopy was normal. The complete blood count revealed mild microcytic hypochromic anemia with hemoglobin 11 g/dL and lymphopenia of 0.57 x 10 9 /L (1.5-3.5). Abnormal biochemical blood investigations included creatinine: 183 µmol/L, urea: 14.3 mmol/L, and albumin: 21 g/L. However, electrolytes, liver enzymes, bilirubin, cardiac enzymes, and lipid profile were all within normal limits. Cyclosporine through level was 127 ng/mL. Serology tests for heaptitis B and C, HIV, Ebstein-barr virus and cytomegalovirus were all negative.
Renal allograft ultrasound revealed a normal sized and echotexture kidney. Doppler ultrasound revealed low perfusion in the transplanted kidney with stenosis at the transplant anastomotic site estimated to be less than 60%. Resistivity index was 0.87 and peak systolic velocity of 580 cm/second.
Chest x-ray [Figure 2] showed opacification of the left hemithorax with decreased volume and fibrotic changes as well as pleural thickening/effusion. The right lung field showed diffuse interstitial opacities. High resolution CT scan [Figure 3] showed consolidation and cavitation involving the left upper and lower lobes. Patchy nodules were noted on the right in addition to bilateral pleural and mild pericardial effusion. X-ray of the cervical spine revealed degenerative changes involving C2-6 and bilateral cervical ribs.
Skin biopsy [Figure 4] was consistent with Kaposi's sarcoma (KS). Electrocardiogram (ECG) showed nonspecific ST-T changes.
Sputum was positive for acid fast bacilli and MTB complex by polymerase chain reaction. Culture yielded Mycobacterium tuberculosis B) sensitive to isoniazid (INH), rifampicin, pyrazinamide and ethambutol. The patient was placed on all these anti-Tubercular drugs. He improved clinically, with partial regression of the KS lesions, gradual ambulation, and improvement in renal function with a decrease of s. creatinine to 140 µmol/L at the time of discharge.
| Discussion|| |
The post transplant period is traditionally divided into early and late transplant periods. Most authors use the 1- year limit to define the onset of late post transplant period. 
TB can occur anytime post-transplantation, though in most instances it develops in the first few months when immunosuppression is maximal; hence, it is considered as an early period opportunistic infection.  Renal transplant patients are at increased risk of disseminated TB (40-60% compared to 0.6-1.4% in the general population) due to immunosupression.  It is difficult to exclude dissemination in our patient, especially with the finding of pericardial effusion, although this could be due to hypoalbuminemia. The treatment of post transplant TB is essentially the same as in the general population. 
The presentation of KS in our patient is relatively early considering the published median interval of about 30 months was reported. , Since the recognition of human herpes virus type 8 (HHV8) in KS lesions in an AIDS patient in 1994,  it is accepted that HHV8 plays a key role in the pathogenesis of KS. The treatment of post transplant KS varies between institutions, but there is a consensus that immunosuppressive medications should be reduced.  More recently, there are several reports of the effectiveness of sirolimus, an antiproliferative agent in the treatment of post transplant KS. , However, a study by Bora tynska et al suggests that regression of KS is a result of diminished immunosuppression, not the direct antineoplastic effect of sirolimus. 
The elevated creatinine in our patient at presentation was multifactorial. He had sonographic evidence of renal artery stenosis although no intervention was contemplated because he had good blood pressure control and renal function improved on medical treatment. The patient also has many of the recognized risk factors for chronic allograft dysfunction namely diabetes mellitus, uncontrolled hypertension, proteinuria, and hypoalbuminemia.  Poor compliance is also a possibility, as this patient did not come with a medical report from his primary physician and failed to come for followup after discharge despite contacts by phone. Poor compliance is also a recognized risk factor for chronic allograft dysfunction.  In addition to uncontrolled hypertension, the patient also had diabetes and pre-transplant ischemic heart disease as risk factors for cardiovascular disease. The peculiarity of his presentation is the concurrence Kaposi's sarcoma and TB concurrently and relatively early post transplantation, which suggests over immunosuppression. Despite these complications, the patient responded to treatment and was discharged from the hospital.
| Acknowledgement|| |
We are grateful to Dr. Ihsan Housaini who provided the pathology slides.
| References|| |
|1.||Sahadevan M, Kasiske BL. Long-term posttransplant management and complications. In: Danovitch GM, ed. Handbook of kidney transplantation. Fourth Edition. Lippincot Williams & Wilkins. 2005:234-76. |
|2.||Mansy H, Al-Harbi A, Somorin A, El-Shadly M, Jaber K. Kaposi's sarcoma and cold abscess of the graft in a renal transplant recipient. Nephrol Dial Transplant 1998;13(3):789-91. |
|3.||Le Roux FB, Burman ND, Becker WB. Kaposi's sarcoma in a renal allograft recipient with cytomegalovirus infection. A case report. S Afr Med J 1982;62(8):252-3. |
|4.||Wang AY, Li PK, To KF, Lai FM, Lai KN. Coexistence of Kaposi's sarcoma and tuberculosis in a renal transplant recipient. Transplantation 1998;66(1):115-8. |
|5.||Guz G, Arican A, Karakayali H, Demirhan B, Bilgin N, Haberal M. Simultaneous nonHodgkin's and Kaposi's sarcoma in a renal transplant recipient. Transplant Proc 1999;31 (8):3240-1. |
|6.||Sabeel A, Qunibi W, Alfurayh O, al-Meshari K. Simultaneous development of Kaposi's sarcoma and lymphoma in a renal transplant recipient. Am J Kidney Dis 1995;31(4):706-9. |
|7.||Lattes R, Radsiz M, Rial M, Arjento J. Tuberculosis in renal transplant recipients. Transplant Infect Dis 1999;1:98-104. |
|8.||European Best practice guidelines for renal transplantation. Late infections. Nephrol Dial Transplant 2002;17:S39-43. |
|9.||Shmueli D, Shapira Z, Yussim A, Nakache R, Ram Z, Shaharabani E. The incidence of Kaposi's sarcoma in renal transplant patients and its relation to immunosuppression. Transplant Proc 1989;21(1 Pt 3):3209-10. |
|10.||Qunibi WY, Barri Y, Alfurayh O, et al. Kaposi's sarcoma in renal transplant recipients: A report on 26 cases from a single institution. Transplant Proc 1993;25(1):1402-5. |
|11.||Chang Y, Cesarman E, Pessin MS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266(5192):1865-9. |
|12.||Camille F. Kaposi's sarcoma after renal transplantation. Nephrol Dial Transplant. 1998;13:2768-73. |
|13.||Duman S, Toz H, A~qqi G, et al. Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression. Nephrol Dial Transplant 2002;17(5):892-6. |
|14.||Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005;352(13):131723. |
|15.||Boratynska M, Zmonarski SC, Klinger M. Recurrence of Kaposi's sarcoma after increased exposure to sirolimus. Int Immunopharmacol 2006;6(13-14):2018-22. |
Department of Medicine, King Fahad Medical City, P.O. Box 59046, Riyadh 11525
Source of Support: None, Conflict of Interest: None
[Figure 1], [Figure 2], [Figure 3], [Figure 4]